Schöttli, the Swiss based global leader in medical and closure mold making, announced that its shareholders have reached an agreement to sell the company to Husky Injection Molding Systems. The transaction is expected to close in early December.
The deal will allow Husky hot runner customers to benefit from product improvements based on strengthened knowledge, while existing Schöttli customers will have access to Husky's hot runner, controller and injection molding machine products. Schöttli's closures business complements Husky's existing closures business by providing additional technology and capacity in both established and growing markets.
Schöttli is a global leader in a number of select medical applications, such as syringes, infusion/transfusion products, diagnostic systems and feminine care items. Back in 2008, when the Swiss-based private equity advisor CGS acquired a majority stake in Schöttli AG, a buy and build strategy was implemented with add-on acquisitions in China and the United States. The subsequent integration and global organization fueled the company's considerable growth of market share and increased profitability. The focus on innovation led to the development of several new technologies, which will further support the growth path initiated over the recent years.